Trial Profile
TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed non-Hodgkin lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs TI-1007 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms Trident19-H
- Sponsors Timmune Biotech
- 23 Jan 2018 New trial record